Related Experiment Video

Updated: Aug 10, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Mild cognitive impairment: to treat or not to treat

Howard S Kirshner1

  • 1Department of Neurology, Stroke Division, Vanderbilt University School of Medicine, 2100 Pierce Avenue, MCS 320, Nashville, TN 37232, USA. Howard.Kirshner@vanderbilt.edu

Current Neurology and Neuroscience Reports
|November 3, 2005
PubMed

Insights

Current drug therapies show limited success in preventing Alzheimer's disease progression in individuals with mild cognitive impairment (MCI). More research is needed for effective interventions against MCI and dementia.

Area of Science:

  • Neurology
  • Gerontology
  • Pharmacology

Background:

  • Mild cognitive impairment (MCI) involves memory deficits exceeding normal aging but not meeting Alzheimer's disease (AD) criteria.
  • Individuals with MCI have a higher risk of progressing to AD compared to their age-matched peers.
  • Early intervention for MCI aims to prevent or delay the onset of dementia.

Purpose of the Study:

  • To review the efficacy of recent drug therapies in preventing or delaying Alzheimer's disease progression in patients with MCI.
  • To evaluate the outcomes of clinical trials involving donepezil, galantamine, and vitamin E for MCI patients.

Main Methods:

  • Analysis of three distinct clinical trials investigating pharmacological interventions for MCI.
  • Assessment of drug effects on the progression from MCI to Alzheimer's disease.
  • Evaluation of drug safety and side effects.

Main Results:

  • Donepezil showed a modest effect in delaying AD onset in one of two trials, but with problematic side effects.
  • Galantamine was associated with an increased risk of mortality.
  • Vitamin E did not demonstrate effectiveness in preventing cognitive decline in MCI patients.

Conclusions:

  • No current medications are FDA-approved for preventing dementia in individuals diagnosed with MCI.
  • Pharmacological interventions for MCI require further investigation due to modest efficacy and potential adverse effects.
  • Developing effective strategies to manage MCI and prevent dementia progression remains a critical challenge.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...